Selentium Group AG has announced its decision to acquire a 2% equity stake in one of Russia’s largest private medical clinic networks.
The transaction represents a strategic step in expanding Selentium’s footprint in the healthcare sector and supporting the integration of AI-driven medical technologies within clinical infrastructure.
The name of the medical network remains undisclosed under the terms of confidentiality.
Purpose of the Acquisition
The minority stake will allow Selentium Group to strengthen its long-term collaboration with the network and accelerate the rollout of key digital health initiatives, including:
-
deployment of the HippocrAI platform for predictive health analytics and diagnostics
Executive Commentary
Marsel Murtazin, CEO of Selentium Group AG:
“Our goal is not financial speculation but strategic participation. A 2% stake gives us the flexibility to integrate AI solutions directly into the medical infrastructure — improving outcomes, efficiency, and the patient experience.”
Markus Steinmann, CFO:
“Even a small stake in a strong healthcare network provides access to large-scale clinical data, operational insights, and collaborative R&D potential — all crucial for Selentium’s health-tech roadmap.”
Maria Voronova, CLO:
“The transaction is structured under Swiss and Russian corporate law frameworks, ensuring full compliance and data-governance transparency between jurisdictions.”
Kenji Tanaka, COO:
“This partnership enables us to test and optimize HippocrAI and Home Medicine systems in real-world hospital environments before scaling them across regions.”
Liliana Sattor, CBO:
“For us, healthcare is not just a market — it’s a human mission. Even a 2% participation is an investment in the future of medical empathy powered by intelligence.”
Strategic Outlook
The acquisition aligns with Selentium Group AG’s strategy to expand its healthcare ecosystem and establish deeper partnerships across private and public health institutions in Europe and the Middle East.
Following this transaction, Selentium will continue to explore opportunities for further strategic equity participation in health-tech and infrastructure companies operating within the MENA and CIS regions.